Medtronic Wins FDA Clearance for First Noninvasive Cardiac Electrical Mapping System
When a patient has an arrhythmia, doctors usually find it via cardiac mapping. This method involves the insertion of a catheter into the heart through an artery or vein. Medtronic is providing the first commercial noninvasive solution for this approach with the CardioInsight Noninvasive 3D Mapping System. The technology received 510(k) approval from FDA and can be used to map arrhythmias in the upper and lower heart chambers.
The CardioInsight system creates 3-D electroanatomic maps of the heart by collecting electrocardiogram signals from the chest (the patient wears a 252-electrode sensor vest) and combines these with data from a CT scan of the heart (view the animation). A differentiating factor from invasive methods is that the technology provides continuous and simultaneous panoramic mapping of the atria and ventricles, because the vest contours to the patient’s body.
Related Articles
-
The IN.PACT Admiral device will provide a new treatment option for PAD patients.
-
The cognitive app that aims to make daily diabetes management easier and more informative is in the final development stage.
-
Announced at CES 2016, the cognitive app will leverage predictive analytics to help patients better manage their condition.
-
The company will invest €13 million in the facility, which will make drug-coated balloons for peripheral artery disease.
-
The device expands treatment to an additional patient population.
